What this is
- How it works
- How it works isn't classified yet
- Tested for
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
- Main trialPhase 2
- “The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.”In the company’s words, NCT07839936 on ClinicalTrials.gov
- Other names
- LY4636581
Other drugs for Atherosclerosis
- ObicetrapibNewAmsterdam Pharma · Phase 3
- LaroprovstatAstraZeneca · Phase 3
- TemsirolimusMercator MedSystems, Inc. · Phase 3
- PelacarsenNovartis · Phase 3
- OlpasiranAmgen · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
Coming up1
- Aug 2028Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07839936
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Aug 2028 | A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease | |
| Phase 1Recruiting | Oct 2026 | A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026